Brief report of efficacy and side effect profile of crossing over to modified-release capsules of methylphenidate in ADHD patients receiving other treatments: case series

References

• American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 5th ed. Arlington (VA): American Psychiatric Association; 2013; DOI:10.1176/appi.books.9780890425596.
   Google Scholar
• Polanczyk G, de Lima MS, Horta BL, et al. The worldwide prevalence of ADHD: a systematic review and metaregression analysis. Am J Psychiatry. 2007;164:942–948. doi: 10.1176/ajp.2007.164.6.942
   PubMed Web of Science ®Google Scholar
• Shaw M, Hodgkins P, Caci H, et al. A systematic review and analysis of long-term outcomes in attention deficit hyperactivity disorder: effects of treatment and non-treatment. BMC Med. 2012;10:942. doi: 10.1186/1741-7015-10-99
   Web of Science ®Google Scholar
• Treuer T, Gau SS-F, Mendez L, et al. A systematic review of combination therapy with stimulants and atomoxetine for attention-deficit/hyperactivity disorder, including patient characteristics, treatment strategies, effectiveness, and tolerability. J Child Adolesc Psychopharmacol. 2013;23:179–193. doi: 10.1089/cap.2012.0093
   PubMed Web of Science ®Google Scholar
• Frolich J, Banaschewski T, Spanagel R, et al. The medical treatment of attention deficit hyperactivity disorder (ADHD) with amphetamines in children and adolescents. Z Kinder Jugendpsychiatr Psychother. 2012;40:287–300. doi: 10.1024/1422-4917/a000185
   Web of Science ®Google Scholar
• Pliszka SR, Crismon ML, Hughes CW, et al. The Texas Children’s Medication Algorithm Project: revision of the algorithm for pharmacotherapy of attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry. 2006;45:642–657. doi: 10.1097/01.chi.0000215326.51175.eb
   PubMed Web of Science ®Google Scholar
• Castle L, Aubert RE, Verbrugge RR, et al. Trends in medication treatment for ADHD. J Atten Disord. 2007;10:335–342. doi: 10.1177/1087054707299597
   PubMedGoogle Scholar
• Storebo OJ, Krogh HB, Ramstad E, et al. Methylphenidate for attention-deficit/hyperactivity disorder in children and adolescents: Cochrane systematic review with meta-analyses and trial sequential analyses of randomised clinical trials. BMJ. 2015;351:h5203. doi: 10.1136/bmj.h5203
   PubMed Web of Science ®Google Scholar
• Dopfner M, Ose C, Fischer R, et al. Comparison of the efficacy of two different modified release methylphenidate preparations for children and adolescents with attention-deficit/hyperactivity disorder in a natural setting: comparison of the efficacy of medikinet® retard and concerta® —a randomized, controlled, double-blind multicenter clinical crossover trial. J Child Adolesc Psychopharmacol. 2011;21:445–454. doi: 10.1089/cap.2010.0082
   PubMed Web of Science ®Google Scholar
• Coghill D, Banaschewski T, Zuddas A, et al. Long-acting methylphenidate formulations in the treatment of attention-deficit/hyperactivity disorder: a systematic review of head-to-head studies. BMC Psychiatry. 2013;13:942. doi: 10.1186/1471-244X-13-237
   Web of Science ®Google Scholar
• American Psychiatric Association. Diagnostic and statistical manual of mental disorders, fourth edition, text revision (DSM-IV-TR). 4th ed. Arlington (VA): American Psychiatric Association; 2000; DOI:10.1176/appi.books.9780890423349.
   Google Scholar
• Turgay A. Disruptive behavior disorders child and adolescent screening and rating scale for children, adolescents, parents, and teachers. West Blomfield (MI): Integr. Ther. Inst. Publ.; 1994.
   Google Scholar
• Ercan ES, Amado S, Somer O, et al. Development of a test battery for the assessment of attention deficit hyperactivity disorder. Çocuk ve Gençlik Ruh Sağlığı Derg. Çocuk ve Gençlik Ruh Sağlığı Derg. Turkish J Child Adolesc Ment Heal. 2001;8:132–144.
   Google Scholar
• National Institute of Mental Health. CGI (Clinic Global Impression) Scale. Psychopharmacol Bull. 1985;21:839–843.
   Web of Science ®Google Scholar
• Barkley RA, McMurray MB, Edelbrock CS, et al. Side effects of methylphenidate in children with attention deficit hyperactivity disorder: a systemic, placebo-controlled evaluation. Pediatrics. 1990;86:184–192.
   PubMed Web of Science ®Google Scholar
• Durand-Rivera A, Alatorre-Miguel E, Zambrano-Sanchez E, et al. Methylphenidate efficacy: immediate versus extended release at short term in Mexican children with ADHD assessed by Conners scale and EEG. Neurol Res Int. 2015: 2015:207801.
   Google Scholar
• Punja S, Zorzela L, Hartling L, et al. Long-acting versus short-acting methylphenidate for paediatric ADHD: a systematic review and meta-analysis of comparative efficacy. BMJ Open. 2013;3:e002312.
   PubMed Web of Science ®Google Scholar
• Garnock-Jones KP, Keating GM. Atomoxetine: a review of its use in attention-deficit hyperactivity disorder in children and adolescents. Paediatr Drugs. 2009;11:203–226.
   Google Scholar
• Reed VA, Buitelaar JK, Anand E, et al. The safety of atomoxetine for the treatment of children and adolescents with attention-deficit/hyperactivity disorder: a comprehensive review of over a decade of research. CNS Drugs. 2016;30:603–628. doi: 10.1007/s40263-016-0349-0
   PubMed Web of Science ®Google Scholar
• Swanson JM, Wigal SB, Wigal T, et al. A comparison of once-daily extended-release methylphenidate formulations in children with attention-deficit/hyperactivity disorder in the laboratory school (The Comacs Study). Pediatrics. 2004;113:e206–e216. available at http://pediatrics.aappublications.org/content/113/3/e206.abstract. doi: 10.1542/peds.113.3.e206
   PubMed Web of Science ®Google Scholar
• Sobanski E, Döpfner M, Ose C, et al. A non-interventional study of extended-release methylphenidate in the routine treatment of adolescents with ADHD: effectiveness, safety and adherence to treatment. ADHD Atten Deficit Hyperact Disord. 2013;5:387–395. doi: 10.1007/s12402-013-0113-y
   Google Scholar